标题
Dacomitinib: First Global Approval
作者
关键词
-
出版物
DRUGS
Volume 78, Issue 18, Pages 1947-1953
出版商
Springer Nature
发表日期
2018-11-30
DOI
10.1007/s40265-018-1028-x
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Efficacy and safety of single-agent pan-human epidermal growth factor receptor (HER) inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer
- (2018) S. Cavalieri et al. EUROPEAN JOURNAL OF CANCER
- Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer and EGFR-Activating Mutations
- (2018) Tony S. Mok et al. JOURNAL OF CLINICAL ONCOLOGY
- Dacomitinib versus gefitinib as first-line treatment for patients with EGFR -mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
- (2017) Yi-Long Wu et al. LANCET ONCOLOGY
- Phase II trial of dacomitinib, a pan–human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification
- (2017) Juan Manuel Sepúlveda-Sánchez et al. NEURO-ONCOLOGY
- Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancers
- (2017) Helena A. Yu et al. Journal of the National Comprehensive Cancer Network
- Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials
- (2016) S. S. Ramalingam et al. ANNALS OF ONCOLOGY
- Use of the epidermal growth factor receptor inhibitors gefitinib, erlotinib, afatinib, dacomitinib, and icotinib in the treatment of non-small-cell lung cancer: a systematic review
- (2015) P.M. Ellis et al. Current Oncology
- Phase II trial of dacomitinib in patients with HER2-positive gastric cancer
- (2015) Do-Youn Oh et al. Gastric Cancer
- Investigation of the impact of hepatic impairment on the pharmacokinetics of dacomitinib
- (2015) Nagdeep Giri et al. INVESTIGATIONAL NEW DRUGS
- Effect of food or proton pump inhibitor treatment on the bioavailability of dacomitinib in healthy volunteers
- (2015) Ana Ruiz-Garcia et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Preclinical Test of Dacomitinib, an Irreversible EGFR Inhibitor, Confirms Its Effectiveness for Glioblastoma
- (2015) C. Zahonero et al. MOLECULAR CANCER THERAPEUTICS
- A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib
- (2014) Karen L. Reckamp et al. CANCER
- Phase II Clinical and Exploratory Biomarker Study of Dacomitinib in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck
- (2014) Han Sang Kim et al. CLINICAL CANCER RESEARCH
- Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial
- (2014) Peter M Ellis et al. LANCET ONCOLOGY
- Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial
- (2014) Pasi A Jänne et al. LANCET ONCOLOGY
- Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial
- (2014) Suresh S Ramalingam et al. LANCET ONCOLOGY
- Unknown
- (2014) Petros Grivas et al. MOLECULAR MEDICINE
- A phase I, open-label, mass balance study of [14C] dacomitinib (PF-00299804) in healthy male volunteers
- (2013) Carlo L. Bello et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A phase I open-label study to investigate the potential drug-drug interaction between single-dose dacomitinib and steady-state paroxetine in healthy volunteers
- (2013) Ana Ruiz-Garcia et al. JOURNAL OF CLINICAL PHARMACOLOGY
- A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck
- (2012) A. R. Abdul Razak et al. ANNALS OF ONCOLOGY
- Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan–Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer
- (2012) Suresh S. Ramalingam et al. JOURNAL OF CLINICAL ONCOLOGY
- The effect of dacomitinib (PF-00299804) on CYP2D6 activity in healthy volunteers who are extensive or intermediate metabolizers
- (2011) Carlo L. Bello et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors
- (2011) P. A. Janne et al. CLINICAL CANCER RESEARCH
- Evaluation of the Antitumor Effects and Mechanisms of PF00299804, a Pan-HER Inhibitor, Alone or in Combination with Chemotherapy or Targeted Agents in Gastric Cancer
- (2011) H.-J. Nam et al. MOLECULAR CANCER THERAPEUTICS
- Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor
- (2008) A. J. Gonzales et al. MOLECULAR CANCER THERAPEUTICS
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started